Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 36

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 36
---
 basis to reflect our receipt of the net proceeds from our sale and issuance of 1,503,500 shares of common stock in this offering based on the offering price of $0.715 per share of common stock, after deducting Placement Agent fees and estimated offering expenses of approximately $166,375.22 payable by us and after the use of net proceeds therefrom. |

<div align='center'>S-21</div>

You should read the following table in conjunction with “ Use of Proceeds,” “ Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included in this prospectus. The following table sets forth our cash, cash equivalents and short-term investments and capitalization as of September 30, 2024 (in thousands):

|                                                                                                                                                                                                                                                                         |     | Actual |             |   |     | Pro Forma(1) |             |   |     | Pro Forma      
 as adjusted(1) |             |   |
|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-------|------------:|:--|:----|:-------------|------------:|:--|:----|:---------------|------------:|:--|
| Cash, cash equivalents, and short-term investments                                                                                                                                                                                                                      |     | $      |   5,012,185 |   |     | $            |   5,014,640 |   |     |                |   6,938,364 |   |
| Total long-term liabilities                                                                                                                                                                                                                                             |     | $      |     147,895 |   |     | $            |     147,985 |   |     |                |     147,985 |   |
| Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 issued and outstanding as of September 30, 2024, actual, 76,480 issued and outstanding, pro forma, and 76,480 issued and outstanding, pro forma as adjusted.                           |     | $      |   9,567,439 |   |     | $            |   9,567,439 |   |     |                |   9,567,439 |   |
| Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2024; 1,861,914 shares issued and outstanding at September 30, 2024;